Athira Pharma shares are trading lower after the company announced its Phase 2/3 LIFT-AD clinical trial for Fosgonimeton in mild-to-moderate Alzheimer's disease did not meet its primary or key secondary endpoints.
Portfolio Pulse from Benzinga Newsdesk
Athira Pharma's shares dropped after the company's Phase 2/3 LIFT-AD trial for Fosgonimeton in Alzheimer's disease failed to meet primary and key secondary endpoints.
September 03, 2024 | 8:32 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Athira Pharma's stock is negatively impacted as their clinical trial for Fosgonimeton in Alzheimer's disease did not meet its primary or key secondary endpoints.
The failure to meet primary and key secondary endpoints in a clinical trial is a significant setback for a biotech company, often leading to a decrease in stock price due to reduced investor confidence in the product's potential success.
CONFIDENCE 100
IMPORTANCE 90
RELEVANCE 100